Results 61 to 70 of about 2,977,193 (214)

Antinuclear antibodies during Puva therapy

open access: yesActa Dermato-Venereologica, 1979
During PUVA therapy 7 patients out of 34 with severe psoriasis developed circulating antinuclear antibodies (ANA) (21%). Before treatment only 3 patients of 50 (6%) considered for PUVA had detectable ANA. The ANA titres were usually low. Antibodies against native DNA as studied with the Crithidia luciliae test, were not found, and blood and urinary ...
M, Bjellerup   +4 more
openaire   +2 more sources

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1702-1712, October 2026.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn   +17 more
wiley   +1 more source

Methoxsalen-induced macular toxicity

open access: yesIndian Journal of Ophthalmology, 2017
Psoralen compounds such as methoxsalen are photosensitizer agents used in conjunction with ultraviolet A (UVA) radiation exposure as photochemotherapy (Psoralens and ultraviolet-A therapy [PUVA therapy]) for certain epidermal skin disorders such as ...
Aditya Maitray, Pukhraj Rishi
doaj   +1 more source

Tracing the Photoaddition of Pharmaceutical Psoralens to DNA

open access: yesMolecules, 2020
The psoralens 8-methoxypsoralen (8-MOP), 4,5′,8-trimethylpsoralen (TMP) and 5-methoxypsoralen (5-MOP) find clinical application in PUVA (psoralen + UVA) therapy. PUVA treats skin diseases like psoriasis and atopic eczema.
Janina Diekmann   +3 more
doaj   +1 more source

Assessment of Treatment Response in Patients With Scleromyxedema by the Double Modified Rodnan Skin Score

open access: yesJEADV Clinical Practice, Volume 5, Issue 3, Page 917-921, September 2026.
ABSTRACT Background Scleromyxedema (SMX) is a cutaneous mucinosis characterised by an abnormal accumulation of mucin in the skin and limited treatment options. Assessment of therapy response during treatment is challenging. Objectives Patients with SMX receiving high‐dose intravenous IVIg therapy were included to assess validity of the double modified ...
Julia K. Winkler, Alexander H. Enk
wiley   +1 more source

Photoprotective practices in patients with mycosis fungoides: a questionnaire‐based survey study

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Ioannis‐Alexios Koumprentziotis   +6 more
wiley   +1 more source

Juvenile Mycosis Fungoides: A Multicenter Retrospective Italian Study

open access: yesJEADV Clinical Practice, Volume 5, Issue 3, Page 839-845, September 2026.
This multicenter retrospective study included 29 juvenile mycosis fungoides (JMF) patients from five Italian centres with confirmed histopathological diagnosis. most often presents with hypopigmented/classic variants and CD8+ phenotype. Early‐onset cases ( < 14 years) show better long‐term outcomes.
Andrea Michelerio   +8 more
wiley   +1 more source

Micose fungóide: estudo epidemiológico de 17 casos e avaliação da resposta terapêutica à PUVA Mycosis fungoides: epidemiologic study of 17 cases and evaluation of PUVA photochemotherapy

open access: yesAnais Brasileiros de Dermatologia, 2006
FUNDAMENTOS: A fotoquimioterapia com PUVA é indicada para tratamento da micose fungóide, empregada como monoterapia em estágios precoces ou combinada a outras drogas nos estágios mais avançados da doença.
Ida Duarte, Roberta Buense, Simone Aoki
doaj   +1 more source

Blocking or enhancing effects of some basic emollients in UVA penetration [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2018
: Background: Topical agents used in combination with phototherapy or photochemotherapy may have both blocking or enhancing effects in ultraviolet rays.
Sevgi Akarsu   +3 more
doaj   +1 more source

Brentuximab Vedotin‐Induced Rash Sparing CD30‐Positive Mycosis Fungoides Lesions

open access: yesJEADV Clinical Practice, Volume 5, Issue 3, Page 971-973, September 2026.
Capsule Summary ABSTRACT Brentuximab vedotin (BV) is an effective treatment for CD30‐positive lymphomas, including mycosis fungoides (MF). However, its use can be associated with various cutaneous adverse effects, including rashes. This case describes a 60‐year‐old male with stage IIB MF who developed a drug‐induced erythematous rash after three ...
Isabel Hariri   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy